# US 2020/0392183 A1 · Immunogenic wt-1 peptides and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0392183 A1
- Document ID: US20200392183A1
- Status: Published application
- Kind: A1
- Application number: 17/007,415
- Filed: 2020-08-31
- Published: 2020-12-17
- Earliest claimed: 2013-01-15
- Assignees: Memorial Sloan Kettering Cancer Center
- Applicants: Memorial Sloan Kettering Cancer Center
- Inventors: David A. SCHEINBERG; Tao Dao
- Web page: https://patentgrep.com/patent/US20200392183A1

## CPC

- C07K 7/06: having 5 to 11 amino acids
- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 14/4748: {Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

This invention provides peptides, immunogenic compositions and vaccines, and methods of treating, reducing the incidence of, and inducing immune responses to a WT1-expressing cancer, comprising heteroclitic peptides derived from the WT-1 protein.

## Claims

### Claim 1

(canceled)

### Claim 2 (depends on 19)

The isolated peptide of claim 19 consisting of the amino acid sequence selected from among CMTWNYMNLGATLKG (SEQ ID NO: 10), WNYMNLGATLKGVAA (SEQ ID NO:11), WNYMNLGATLKGVAA (SEQ ID NO:19), TWNYMNLGATLKGVA (SEQ ID NO:20), and CMTWNYMNLGATLKGVA (SEQ ID NO:23).

### Claim 3

(canceled)

### Claim 4 (depends on 19)

The isolated peptide of claim 19 comprising the amino acid sequence selected from among CMTWNYMNLGATLKG (SEQ ID NO: 10), WNYMNLGATLKGVAA (SEQ ID NO:11), WNYMNLGATLKGVAA (SEQ ID NO:19), TWNYMNLGATLKGVA (SEQ ID NO:20), and CMTWNYMNLGATLKGVA (SEQ ID NO:23).

### Claim 5 (depends on 19)

The isolated peptide of claim 19, wherein said isolated peptide binds to an HLA class I molecule, an HLA class II molecule, or the combination thereof.

### Claim 6

(canceled)

### Claim 7

(canceled)

### Claim 8

An isolated class II binding peptide selected from CMTWNYMNLGATLKG (SEQ ID NO:10), WNYMNLGATLKGVAA (SEQ ID NO:11), MTWNYMNLGATLKGV (SEQ ID NO:19), TWNYMNLGATLKGVA (SEQ ID NO:20), and CMTWNYMNLGATLKGVA (SEQ ID NO:23).

### Claim 9 (depends on 19)

A pharmaceutical composition comprising a peptide of claim 19 and a pharmaceutically acceptable carrier, vehicle or excipient.

### Claim 10 (depends on 19)

A vaccine comprising (a) one or more isolated peptides of claim 19, and (b) an adjuvant or a carrier.

### Claim 11 (depends on 10)

The vaccine of claim 10, wherein said adjuvant is QS21, Freund's incomplete adjuvant, aluminum phosphate, aluminum hydroxide, BCG, alum, a growth factor, a cytokine, a chemokine, an interleukin, Montanide ISA 51, or GM-CSF.

### Claim 12 (depends on 10)

A method of treating a subject with a WT1-expressing cancer or reducing an incidence of a WT1-expressing cancer, or its relapse, the method comprising administering to said subject the vaccine of claim 10, thereby treating a subject with a WT1-expressing cancer, reducing an incidence of a WT1-expressing cancer or its relapse therein.

### Claim 13 (depends on 12)

The method of claim 12, wherein said WT1-expressing cancer is a leukemia, a desmoplastic small round cell tumor, a gastric cancer, a colon cancer, a lung cancer, a breast cancer, a germ cell tumor, an ovarian cancer, a uterine cancer, a thyroid cancer, a liver cancer, a renal cancer, a Kaposi's sarcoma, a sarcoma, a hepatocellular carcinoma, a Wilms' tumor, an acute myelogenous leukemia (AML), a myelodysplastic syndrome (MDS), mesothelioma, or a non-small cell lung cancer (NSCLC).

### Claim 14 (depends on 10)

A method of inducing the formation and proliferation of CTL specific for cells of a WT1-expressing cancer, the method comprising administering to said subject the vaccine of claim 10, thereby inducing the formation and proliferation of CTL specific for cells of a WT1-expressing cancer.

### Claim 15 (depends on 14)

The method of claim 14, wherein said WT1-expressing cancer is a leukemia, a desmoplastic small round cell tumor, a gastric cancer, a colon cancer, a lung cancer, a breast cancer, a germ cell tumor, an ovarian cancer, a uterine cancer, a thyroid cancer, a liver cancer, a renal cancer, a Kaposi's sarcoma, a sarcoma, a hepatocellular carcinoma, a Wilms' tumor, an acute myelogenous leukemia (AML), a myelodysplastic syndrome (MDS), mesothelioma, or a non-small cell lung cancer (NSCLC).

### Claim 16 (depends on 19)

A composition comprising (a) an antigen-presenting cell and (b) a peptide of claim 19.

### Claim 17

(canceled)

### Claim 18

(canceled)

### Claim 19

An isolated peptide comprising the amino acid sequence NYMNLGATL (SEQ ID NO:7) other than the isolated peptide consisting of the amino acid sequence NYMNLGATL (SEQ ID NO:7).

### Claim 20 (depends on 2)

An isolated peptide of claim 2 consisting of the amino acid sequence WNYMNLGATLKGVAA (SEQ ID NO:11).

### Claim 21

An isolated class II binding peptide having the sequence WNYMNLGATLKGVAA (SEQ ID NO:11).

### Claim 22 (depends on 19)

A nucleic acid molecule encoding a peptide comprising the isolated peptide of claim 19.

### Claim 23 (depends on 22)

A vector comprising the nucleic acid molecule of claim 22.

### Claim 24 (depends on 23)

The vector of claim 23, further comprising an immunomodulatory compound.

### Claim 25 (depends on 22)

A pharmaceutical composition comprising the nucleic acid of claim 22 or a vector thereof.

### Claim 26 (depends on 22)

A method of treating a subject with a WT1-expressing cancer or reducing an incidence of a WT1-expressing cancer, or its relapse, the method comprising administering to said subject the nucleic acid of claim 22 or a vector thereof, thereby treating a subject with a WT1-expressing cancer, reducing an incidence of a WT1-expressing cancer or its relapse therein.

### Claim 27 (depends on 26)

The method of claim 26, wherein said WT1-expressing cancer is a leukemia, a desmoplastic small round cell tumor, a gastric cancer, a colon cancer, a lung cancer, a breast cancer, a germ cell tumor, an ovarian cancer, a uterine cancer, a thyroid cancer, a liver cancer, a renal cancer, a Kaposi's sarcoma, a sarcoma, a hepatocellular carcinoma, a Wilms' tumor, an acute myelogenous leukemia (AML), a myelodysplastic syndrome (MDS), mesothelioma or a non-small cell lung cancer (NSCLC).
